Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients

The role of IgE autoantibodies has been demonstrated in the pathogenesis of bullous pemphigoid for many years. Recently, omalizumab (OMZ), a humanized monoclonal anti-IgE antibody that depletes total serum IgE, has been used off-label in a few case series of bullous pemphigoids demonstrating a rapid...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Marina Alexandre, Gérôme Bohelay, Thomas Gille, Christelle Le Roux-Villet, Isaac Soued, Florence Morin, Frédéric Caux, Sabine Grootenboer-Mignot, Catherine Prost-Squarcioni
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2022-04-01
Saila:	Frontiers in Immunology
Gaiak:	omalizumab (Xolair) mucous membrane pemphigoid (MMP) bullous pemphigoid (BP) autoimmune bullous diseases (AIBDs) autoimmune skin diseases Immunoglobulin E (IgE)
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.874108/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!